Cortical tau load is associated with white matter hyperintensities
© McAleese et al. 2015
Received: 16 September 2015
Accepted: 17 September 2015
Published: 30 September 2015
Cerebral white matter lesions (WML), visualized as white matter hyperintensities (WMH) on T2-weighted MRI, encompass structural damage and loss of integrity of the cerebral white matter (WM) and are commonly assumed to be associated with small vessel disease (SVD). However, it has been suggested that WM damage may also be the result of degenerative axonal loss that is secondary to cortical Alzheimer’s disease (AD) pathologies i.e., hyperphosphorylated tau (HPτ) and amyloid-beta (Aβ). Here we investigate the influence of HPτ, Aβ and SVD on WMH severity.
36 human post-mortem right fixed cerebral hemispheres (mean age 84.4 ± 7.7 years; male: 16, female: 20) containing varying amounts of AD-pathology (AD: 23, controls: 13) underwent T2- weighted MRI with WMH assessed according to the age related white matter change scale (ARWMC). After dissection, using tissue samples from the frontal, temporal, parietal and occipital regions from the right hemisphere, we quantitatively assessed cortical HPτ and Aβ pathology burden by measuring the percentage area covered by AT8 immunoreactivity (HPτ-IR) and 4G8 immunoreactivity (Aβ-IR), and assessed the severity of WM SVD by calculating the sclerotic index (SI) of WM arteries/arterioles. HPτ-IR, Aβ-IR, and SI were compared with ARWMC scores. HPτ-IR, Aβ-IR and WM ARWMC scores were all significantly higher in AD cases compared to controls, while SI values were similar between groups. ARWMC scores correlated with HPτ-IR, Aβ-IR and SI in various regions, however, linear regression revealed that only HPτ-IR was a significant independent predictor of ARWMC scores.
Here we have shown that increasing cortical HPτ burden independently predicted the severity of WMH indicating its potentially important role in the pathogenesis of WM damage. Moreover, our findings suggest that in AD patients the presence of WMH may indicate cortical AD-associated pathology rather than SVD. Further studies are warranted to elucidate the pathological processes that lead to WM damage and to clarify if WMH may serve as a general biomarker for cortical AD-associated pathology.
KeywordsHyperphosphorylated tau White matter hyperintensities White matter lesions Small vessel disease Alzheimer’s disease Post-mortem MRI
Cerebral white matter lesions (WML), as visualized histologically, encompass structural damage and loss of integrity of the cerebral white matter (WM) due to WM rarefaction (i.e., demyelination and axonal loss), which is commonly accompanied by reactive astrocytosis and edema . WML frequently occur in brains of both demented and non-demented elderly, and are visualized as white matter hyperintensities (WMH) on pre- and post-mortem T2-weighted magnetic resonance imaging (MRI) . Age-associated deep WM changes are distinguishable as ‘punctate’, i.e., single lesions <10 mm, ‘early confluent’, i.e., single lesion <20 mm and/or multiple lesions 10–20 mm linked by ‘connecting bridges’, or ‘confluent’ changes, i.e., confluent area of damage >20 mm in diameter . These lesions differ from that seen in multiple sclerosis (MS) as MS WML are typically ovoid in shape, range between 3-8 mm in diameter and are mainly located in the periventricular WM, posterior fossa and subcortical structures . The Austrian Stroke prevention study indicated that the prevalence of WMH is between 62–96 % in individuals aged 45 to 87 years . WMH are associated with a wide range of cognitive deficits, such as cognitive decline , and are a frequent co-pathology in Alzheimer’s disease (AD) , which is the most frequent cause of age-associated dementia . The pathogenesis of WMH is typically associated with small vessel disease (SVD) of the WM , however; the pathogenic mechanisms underlying the development of WM damage are not well understood. Previous longitudinal, neuropathological and imaging studies suggest a multifactorial aetiology of WML [13, 16, 32, 33, 58, 62] including WM damage secondary to both SVD- related ischemia and cortical AD pathology, i.e., depositions of intracellular hyperphosphorylated tau (HPτ) and extracellular amyloid-beta (Aβ). SVD alterations are assumed to lead to disturbed arterial autoregulation, promoting progressive stenosis that eventual leads to chronic hypoperfusion of the surrounding WM . The exact pathological mechanisms of degenerative axonal loss is still unclear, but it is suggested axonal death occurs in conjunction with AD-pathology related grey matter atrophy, or via calpain-mediated degradation of cytoskeletal proteins, activated by AD pathology-related axonal transport dysfunction [9, 36]. However, currently neither imaging nor routine histological techniques allow for differentiation between ischemic (SVD-related) or neurodegenerative causes (AD pathology) of WM damage.
Previous studies investigating the relationship between WM damage with both cortical neurodegenerative pathology and WM SVD used semi-quantitative methods to evaluate the severity of the respective pathology [13, 24, 35]. However, such semi-quantitative methods provide only a crude estimation of the severity of pathology , while quantitative methods more accurately reflect the actual amount of pathology present. Therefore, we quantitatively measured cortical HPτ and Aβ burden, as well as the degree of vessel wall thickening of WM arteries/arterioles in human post-mortem brains, to determine the influence of both cortical AD pathology and SVD on WM integrity that was assessed using post-mortem T2-weighted MRI.
Materials and methods
Characteristics of study cohort
Statistic (df, p-value)
Age, mean (±SD)
84.26 years (5.67)
t(34) = 1.194, p = 0.241
χ 2 (1) = 0.444, p = 0.505
PMD, mean (±SD)
49.95, h (22.89)
t(33) = 0.34, p = 0.735
Thal Aβ phase20
Phase 5, n = 23
Phase 0, n = 5
U(34) = 0.000, p = 0.001
Phase 1, n = 3
Phase 2, n = 3
Phase 3, n = 1
Phase 4, n = 1
Braak NFT stage21
NFT stage 6, n = 23
NFT stage 0, n = 2
U(34) = 0.000, p = 0.001
NFT stage 1, n = 1
NFT stage 2, n = 3
NFT stage 3, n = 6
NFT stage 4, n = 1
C, n = 23
Negative, n = 10
A, n = 2
B, n = 1
High, n = 23
No, n = 5
Low, n = 7
Intermediate, n = 1
t(22) = 14.07, p = 0.001
Post-mortem magnetic resonance imaging
We have previously demonstrated that post-mortem MRI of fixed hemispheres reliably reflect WM damage as accurately as an extensive histological assessment at 7 mm intervals . Briefly, fixed right hemispheres were removed from formalin solution and were investigated using a 4.7 T MRI scanner (Bruker Medical, Ettlingen, Germany): Bruker Biospec 47/60 VAS, (vertical, actively shielded, the inner-bore width of 60 cm) fitted with a BGA-38-S gradient system (actively shielded, the inner-bore width of 38 cm) and a birdcage radio-frequency coil with a working cross-section of 170 × 240 mm. AT2-weighted pulse sequence was used: two spin echo images of effective echo time (TE) = 32/96 ms, repetition time (TR) = 8200 ms, with slice thickness of 2 mm and planar resolution of 1.0 × 0.78 mm. Regional WMH were subjectively rated, blinded to clinical diagnosis, by two experienced assessors (M.F & J.T.O) according to the age-related white matter change scale (ARWMC) ; score 0, absence of WMH; score 1, ‘punctate’ WMH (<10 mm); score 2, ‘early confluent’ WMH (<20 mm); score 3, ‘confluent’ WMH (>20 mm). ARWMC scores were generated for the frontal and temporal WM and a combined score for the parietal and occipital WM i.e., parieto-occipital. All ARWMC scores were combined to calculate mean total ARWMC score that reflected WMH severity of the entire hemisphere.
Routine neuropathological assessment
Irrespective of clinical diagnoses, all brains underwent neuropathological assessment to standardized neuropathological scoring/grading systems, including Thal phases of Aβ deposition , Braak staging of neurofibrillary pathology , Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) scores  and the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria  (Table 1).
Six μm paraffin-embedded sections were cut from six cerebral regions; pre-frontal cortex (Brodmann area (BA) 10, 9), mid-frontal cortex (BA 8, 9), entorhinal cortex (BA 36, 28), temporal cortex (BA 36), parietal cortex (BA 40/22), and occipital cortex (BA 17). Tissue sections were mounted onto 4 % 3-aminopropyltriethoxysilane (APES)-coated glass slides and histologically stained with haematoxylin and eosin (H&E). Immunohistochemistry was performed for HPτ (antibody AT8; dilution 1:4000; Innogenetics, Ghent, Belgium) and Aβ peptide (clone 4G8; dilution 1:15,000; Signet Labs, Dedham, MA, USA). Prior to immunostaining, antigen retrieval was performed by microwaving slides in 0.01 mL citrate buffer for 10 min (AT8) or immersed for 1 hour in concentrated formic acid (4G8). Immunopositivity was detected using the Menarini X-Cell-Plus HRP Detection Kit (Menarini Diagnostics, Winnersh-Wokingham, UK) with 3,3 diaminobezidine (DAB) as a chromagen and haematoxylin as a counter stain. Sections were subsequently dehydrated through a series of alcohols, cleared and mounted using DPX (CellPath, Powys, UK).
Quantification of protein aggregates - image analysis
The sclerotic index (SI) is a quantitative measure of arterial and arteriolar vessel wall thickness and has been shown to be an accurate indicator for the severity of SVD [31, 61]. The standard formulae SI = 1 - (internal diameter/external diameter) was used; the SI of normal arteries and arterioles ranges from 0.2 to 0.3, while an SI of 0.3 to 0.5 indicates mild to moderate SVD and SI values >0.5 are seen in severe SVD . On H&E stained tissue sections, adjacent to the ones used to determine HPτ-IR (AT8) and Aβ-IR (4G8; Fig. 1), the SI of WM vessels was examined, blinded to neuropathological diagnosis, using a Nikon 90i microscope at 200x magnification. Eight randomly selected cerebral WM arteries and/or arterioles >50 μm diameters were identified per section and a single image captured using a DsFi1 camera. SI was calculated using the software program VasCalc as previously described . SI values from the eight individual vessels from temporal, parietal and occipital WM were used to calculate mean values for each WM region. Eight individual SI values from both the pre- and mid-frontal WM were combined and used to calculate a mean value for the frontal WM. All regional SI scores were taken to calculate a mean total SI value to reflect the severity of SVD in the entire hemispherical WM.
The Statistical Package for Social Sciences software (SPSS ver. 21) was used for statistical evaluation. Variables were tested for normality using the Shapiro-Wilk test and visual inspection of variable histograms. Subsequently, group effects were assessed using either non-parametric (Mann–Whitney U) or parametric procedures (independent samples test). Where appropriate, partial Spearman’s (ρ') and Pearson’s (r') correlation coefficients (one tailed) were used to assess associations between ARWMC scores and HPτ-IR, Aβ-IR and SI (controlling for the effects of age at death). Exploratory forward stepwise linear regression analyses were also conducted to investigate predictors of ARWMC scores.
Differences between total cortical HPτ/Aβ burden, total WM SVD severity and severity of WMH between AD and controls
Correlations between cortical HPτ/Aβ burden and WM SVD severity with severity of WMH
Neuropathological predictors of WMH
To investigate whether the burden of cortical neurodegenerative pathology (i.e., HPτ and Aβ) and severity of SVD in the WM independently predicted WMH score, stepwise linear regression analyses were performed for each region with ARWMC scores as the dependent variables and cortical HPτ-IR, cortical Aβ-IR, WM SI scores and age at death as independent variables.
In the temporal region, only HPτ-IR was a significant predictor (model R2 = 0.270, F(2) = 5.359, p < 0.001; β = 0.532, p = 0.003) while the remaining independent variables were not significant predictors (cortical Aβ-IR: β = 0.081, p = 0.087; WM SI: β = 0.306, p = 0.358; age at death: β = 0.194, p = 0.245). With respect to the frontal and parietal regions, both cortical HPτ-IR (frontal: model R2 = 0.208, F(2) = 4.32, p < 0.001; β = 0.340, p = 0.022; parietal: model R2 = 0.280, F(2) = 6.410, p < 0.001; β = 0.417, p = 0.009) and age at death (frontal: β = 0.398, p = 0.018; parietal: β = 0.384, p = 0.015) were significant predictors but not cortical Aβ-IR (frontal: β = 0.059, p = 0.725; parietal: β = 0.068, p = 0.068) nor WM SI (frontal: β = 0.204, p = 0.248; parietal: β = 0.129, p = 0.149). In the occipital regions, only age at death was a significant predictor (model R2 = 0.135, F(1) = 4.819, p < 0.001; β = 0.367, p = 0.036) but not HPτ-IR (β = 0.297, p = 0.081), Aβ-IR (β = 0.266, p = 0.114) or WM SI (β = 0.147, p = 0.252). With respect to the entire hemisphere, total cortical HPτ-IR (model R2 = 0.331, F(2) = 8.162, p < 0.001; β = 0.514, p = 0.001) and age at death (β = 0.386, p = 0.012) were significant predictors but not total cortical Aβ-IR (β = 0.074, p = 0.075) or total WM SI (β = 0.179, p = 0.235).
Associations between HPτ/Aβ burden and WM SVD with WMH in cases with minimal cortical neurodegenerative pathology
Here, we demonstrate that in frontal, temporal and parietal regions, as well as in the entire hemisphere, cortical HPτ burden predicted the severity of WMH independent of both cortical Aβ burden and WM SVD severity. However, in cases virtually lacking cortical HPτ pathology we found a strong correlation between the severities of SVD and WMH.
WMH is a descriptive term for diffuse, low-density changes of the cerebral WM as seen on T2-weighted MRI images. Despite the assumption that WMH are the result of SVD, the underlying pathogenesis is unclear and appears to be associated with a heterogeneous mixture of vascular and degenerative processes as determined by previous studies [24, 32, 33, 62], and our data that demonstrated increasing WMH severity with increasing cortical HPτ and Aβ pathology, SVD severity, and age. As expected, age at death was associated with increasing WMH severity as age is one of the strongest risk factors related to the development of WMH , as well as being associated with increasing AD-related pathology  and dementia. In agreement with previous studies [4, 47, 50] we found significantly more severe WMH in AD i.e., cognitively impaired cases compared to controls, however, no respective differences were seen with regard to the severity of SVD suggesting that SVD may not be the main underlying cause for WMH in AD. Moreover, only cortical HPτ pathology independently predicted the severity of WMH when calculations were performed for frontal, temporal and parietal regions, as well as the entire hemisphere. These findings further point towards an important role of increasing amounts of cortical HPτ pathology in the pathogenesis of WMH. It is important to note that the accumulation of AD-pathology frequently occurs in normal aged individuals without compromising cognitive function [5, 23, 25, 56], therefore, the impact of HPτ pathology on WM damage may not be restricted to just patients that exhibit cognitive decline or dementia.
This association between increasing HPτ pathology and increasing WMH severity corroborates previous neuropathological-imaging studies that reported an association between increasing Braak NFT stage and increasing WMH severity [13, 24]. Furthermore, tau protein has been implicated in the clinical conversion from MCI to AD as shown in a recent study by Tosto and colleagues, who demonstrated that in MCI participants with high cerebral spinal fluid level of total-tau, higher parietal WMH volume predicted conversion to AD . In addition, our data implicating HPτ pathology as a predictor for WMH severity in the temporal and parietal WM confirms neuropathological studies reporting WM damage in AD to predominately affect the temporal  and parietal  WM. However, these studies were based on semi-quantitative assessment that provides only a crude estimation of pathological burden [6, 55], while our study implemented quantitative assessment that better reflects the actual amount of pathology and seems better suited to identify associations between different types of pathological lesions.
Despite our data indicating WM damage in cases with cognitive impairment is associated with HPτ pathology, the underlying mechanism of how HPτ causes axonal loss remains unclear. Two possible pathomechanisms have been proposed; firstly, neuronal death is associated with the accumulation and deposition of HPτ pathology , which may lead to the disintegration of associated axons. Secondly, in neurodegenerative diseases with protein aggregation and deposition, including AD, major synaptic and axonal loss can precede the loss of the neuronal soma [10, 49]. This type of axonal loss, which is independent of neuronal death, is thought to be the result of dysfunction and/or blockage of fast anterograde axonal transport [9, 42]. With respect to the development of HPτ pathology, the hyperphosphorylation of the microtubule-associated tau protein leads to the destabilization of the principal cytoskeletal component microtubules that are critical for fast anterograde transport in axons . Impairment of axonal transport is thought to activate the cysteine protease calpain, resulting in the retrograde degradation of axonal cytoskeletal proteins and subsequent loss of the axon fibre [9, 36]. Both of these suggested mechanisms might explain our finding of increasing cortical HPτ burden independently predicting the severity of WMH.
In cases with minimal HPτ pathology, categorized as Braak NFT stage 0-II, we found a strong correlation between increasing WM SVD and WMH severities confirming previous pathologic and imaging studies demonstrating an association between SVD and WM damage [45, 52]. Of note, the small sample size of six cases was a limitation and repeat studies are warranted using a larger cohort. This finding is also in agreement with a number of recent contributions that point to the independence of WMH from classical AD biomarkers [27, 29, 43]. On the other hand, in the entire study cohort, cases with higher HPτ pathology burden and cognitive impairment exhibited significantly higher ARWMC scores compared to controls, while no significant differences were seen in the severity of WM SVD. Moreover, the severity of WM SVD failed to predict WMH score. Taken together, our findings suggest that in general, both cortical HPτ pathology and WM SVD may lead to the development of WMH; however, in neurodegenerative diseases such as AD, WMH are primarily associated with cortical HPτ pathology, while WM SVD may be an additional contributing factor. On the other hand, in cases virtually lacking cortical HPτ pathology, WM SVD seems to play an important role in the development of WMH. SVD is complex and heterogeneous and our assessment was limited to the measurement of the vessel wall thickness i.e., measure of fibrosis only, therefore, future studies may warrant assessment of other SVD-related pathologies, e.g., blood brain barrier breakdown and perivascular space enlargement. Additionally, we did not assess other possible causes of ischemic damage such as cerebral amyloid antipathy, orthostatic hypotension, and myocardial infarction.
Our study incorporated the use of post-mortem T2 weighted MR imaging for the assessment of WMH. There is currently limited data directly comparing human in vivo and post-mortem MRI imaging of WMH and the effects of fixation on MR characteristics. One such study by Macchi and colleagues compared MS lesions in vivo and post-mortem MRI scan from a single MS patient and determined that the MRI signal and contrast from the post-mortem scan was satisfactory compared to the in vivo scan . Furthermore, an investigation into the effects of fixation on quantitative MRI of human brain slices revealed there were no significant changes detected in WMH and normal appearing WM after fixation . Further studies are warranted to elucidate any significant alteration of MR characteristics as a result of the fixation process. Nevertheless, MRI and histopathology comparative studies have previously shown that post-mortem MRI of formalin fixed tissue is a reliable method to obtain data on both the severity and distribution of WM damage [14, 15, 38, 52].
Neuroimaging is emerging as an important biomarker in the diagnosis of pre-symptomatic AD and multiple studies have indicated regional specific WM damage in AD patients compared to normal ageing. Reduced fractional anisotropy (indicative of reduced tissue integrity) on diffusion tensor imaging (DTI) is frequently seen in the WM of the posterior regions, i.e., parietal, temporal and occipital lobes [1, 3, 4], as well as the major fiber bundles, i.e., inferior and superior longitudinal fasciculi , the parahippocampus  and corpus callosum . Previous neuroimaging studies have demonstrated associations between increasing changes in WM and cortical atrophy in AD [1, 3], which could possibly be explained by WM damage resulting from axonal loss caused by HPτ-related neuronal death.
Clinical diagnosis and decision making in dementia is partly based on neuroimaging e.g., medial temporal lobe atrophy is associated with AD , while WMH are usually regarded as an indicator of vascular cognitive impairment/dementia . However, given that AD is the most common cause of age-associated dementia , our findings strongly suggest that WMH in cognitively impaired individuals rather indicate cortical AD associated neurodegenerative pathology than SVD/CVD. Hence, current interpretation of WM neuroimaging may result in inadequate management of patients and be detrimental for the stratification of patient cohorts in clinical trials. Further studies are warranted to better determine the underlying pathological processes that may lead to WMH.
We are grateful to the individuals and their families who kindly donated their brains to the Newcastle Brain Tissue Resource. We thank Prof Raj Kalaria and Dr Yumi Yamamoto for access to the VasCalc program, and Lynne Ramsay and Ros Hall for their excellent technical support.
Part of the research was funded by the National Institute for Health Research (NIHR), Newcastle Biomedical Research Centre for Ageing, and Age-related based at Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust and Newcastle University. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. K.E.M is currently funded by the Alzheimer’s Society and previously funded by the Dunhill Medical Trust (grant number R173/1110). Tissue for this study was provided by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the UK Medical Research Council (grant number G0400074) and by Brains for Dementia research, a joint venture between Alzheimer’s Society and Alzheimer’s Research UK.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Agosta F, Pievani M, Sala S, Geroldi C, Galluzzi S, Frisoni GB, Filippi M (2011) White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 258:853–863View ArticlePubMedGoogle Scholar
- Attems J, Neltner JH, Nelson PT (2014) Quantitative neuropathological assessment to investigate cerebral multi-morbidity. Alzheimers Res Ther 6:85PubMed CentralView ArticlePubMedGoogle Scholar
- Bosch B, Arenaza-Urquijo EM, Rami L, Sala-Llonch R, Junque C, Sole-Padulles C, Pena-Gomez C, Bargallo N, Molinuevo JL, Bartres-Faz D (2012) Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol Aging 33:61–74View ArticlePubMedGoogle Scholar
- Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G, Filippi M (2002) White matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 72:742–746PubMed CentralView ArticlePubMedGoogle Scholar
- Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259View ArticlePubMedGoogle Scholar
- Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404PubMed CentralView ArticlePubMedGoogle Scholar
- Ceccarelli A, Bakshi R, Neema M (2012) MRI in multiple sclerosis: a review of the current literature. Curr Opin Neurol 25:402–409View ArticlePubMedGoogle Scholar
- Christiansen P, Larsson HB, Thomsen C, Wieslander SB, Henriksen O (1994) Age dependent white matter lesions and brain volume changes in healthy volunteers. Acta Radiol 35:117–122View ArticlePubMedGoogle Scholar
- Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6:889–898View ArticlePubMedGoogle Scholar
- Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer’s disease. Neurobiol Aging 24:1023–1027View ArticlePubMedGoogle Scholar
- Duyckaerts C, Hauw JJ (1997) Prevalence, incidence and duration of Braak’s stages in the general population: can we know? Neurobiol Aging 18:362–369, discussion 389–392View ArticlePubMedGoogle Scholar
- Englund E (1998) Neuropathology of white matter changes in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 9:6–12View ArticlePubMedGoogle Scholar
- Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81:977–983PubMed CentralView ArticlePubMedGoogle Scholar
- Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43:1683–1689View ArticlePubMedGoogle Scholar
- Fernando MS, O’Brien JT, Perry RH, English P, Forster G, McMeekin W, Slade JY, Golkhar A, Matthews FE, Barber R, Kalaria RN, Ince PG (2004) Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol Appl Neurobiol 30:385–395View ArticlePubMedGoogle Scholar
- Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O’Brien JT, Ince PG (2006) White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37:1391–1398View ArticlePubMedGoogle Scholar
- Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198View ArticlePubMedGoogle Scholar
- Gentleman SM, Allsop D, Bruton CJ, Jagoe R, Polak JM, Roberts GW (1992) Quantitative differences in the deposition of beta A4 protein in the sulci and gyri of frontal and temporal isocortex in Alzheimer’s disease. Neurosci Lett 136:27–30View ArticlePubMedGoogle Scholar
- Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41:17–24View ArticlePubMedGoogle Scholar
- Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJ (2011) Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 82:126–135View ArticlePubMedGoogle Scholar
- Grinberg LT, Thal DR (2010) Vascular pathology in the aged human brain. Acta Neuropathol 119:277–290PubMed CentralView ArticlePubMedGoogle Scholar
- Hachinski VC, Potter P, Merskey H (1987) Leuko-araiosis. Arch Neurol 44:21–23View ArticlePubMedGoogle Scholar
- Ince PG (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357:169–175View ArticleGoogle Scholar
- Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, Ellis WG, Zarow C, Mungas D, Reed BR, Kramer JH, Schuff N, DeCarli C, Chui HC (2008) Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 63:72–80PubMed CentralView ArticlePubMedGoogle Scholar
- Jellinger KA, Attems J (2012) Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 31:87–98View ArticlePubMedGoogle Scholar
- Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T (2004) Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 226:75–80View ArticlePubMedGoogle Scholar
- Kaur B, Himali JJ, Seshadri S, Beiser AS, Au R, McKee AC, Auerbach S, Wolf PA, DeCarli CS (2014) Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord 28:219–225PubMed CentralView ArticlePubMedGoogle Scholar
- Kehoe EG, McNulty JP, Mullins PG, Bokde AL (2014) Advances in MRI biomarkers for the diagnosis of Alzheimer’s disease. Biomark Med 8:1151–1169View ArticlePubMedGoogle Scholar
- Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM (2014) Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 71:855–862View ArticlePubMedGoogle Scholar
- Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S, Ferrer I, Gelpi E, Kovari V, Kretzschmar H, Nagy Z, Parchi P, Seilhean D, Soininen H, Troakes C, Budka H (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26:343–350View ArticlePubMedGoogle Scholar
- Lammie GA, Brannan F, Slattery J, Warlow C (1997) Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke 28:2222–2229View ArticlePubMedGoogle Scholar
- Lee DY, Fletcher E, Martinez O, Ortega M, Zozulya N, Kim J, Tran J, Buonocore M, Carmichael O, DeCarli C (2009) Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology 73:1722–1728PubMed CentralView ArticlePubMedGoogle Scholar
- Lee DY, Fletcher E, Martinez O, Zozulya N, Kim J, Tran J, Buonocore M, Carmichael O, DeCarli C (2010) Vascular and degenerative processes differentially affect regional interhemispheric connections in normal aging, mild cognitive impairment, and Alzheimer disease. Stroke 41:1791–1797PubMed CentralView ArticlePubMedGoogle Scholar
- Lee SH, Coutu JP, Wilkens P, Yendiki A, Rosas HD, Salat DH, I Alzheimer’s disease Neuroimaging (2015) Tract-based analysis of white matter degeneration in Alzheimer’s disease. Neuroscience 301:79View ArticlePubMedGoogle Scholar
- Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, Delacourte A, Defossez A, Rapoport A, Clarisse J et al (1991) Could Wallerian degeneration contribute to “leuko-araiosis” in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 54:46–50PubMed CentralView ArticlePubMedGoogle Scholar
- Ma M, Ferguson TA, Schoch KM, Li J, Qian Y, Shofer FS, Saatman KE, Neumar RW (2013) Calpains mediate axonal cytoskeleton disintegration during Wallerian degeneration. Neurobiol Dis 56:34–46PubMed CentralView ArticlePubMedGoogle Scholar
- Macchi G, Cioffi RP (1992) An in vivo and post mortem MRI study in multiple sclerosis with pathological correlation. Ital J Neurol Sci 13:97–103PubMedGoogle Scholar
- McAleese KE, Firbank M, Hunter D, Sun L, Hall R, Neal JW, Mann DM, Esiri M, Jellinger KA, O’Brien JT, Attems J (2013) Magnetic resonance imaging of fixed post mortem brains reliably reflects subcortical vascular pathology of frontal, parietal and occipital white matter. Neuropathol Appl Neurobiol 39:485View ArticlePubMedGoogle Scholar
- McParland S, McAleese KE, Walker L, Johnson M, Fielder E, Knowles I, Attems J (2013) Tissue Microarray in the quantification of hyper-phosphorylated tau, amyloid-beta and alpha-synuclein. NAN 39:42Google Scholar
- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486View ArticlePubMedGoogle Scholar
- Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11PubMed CentralView ArticlePubMedGoogle Scholar
- Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST (2009) Axonal transport defects in neurodegenerative diseases. J Neurosci Off J Soc Neurosci 29:12776–12786View ArticleGoogle Scholar
- Mortamais M, Artero S, Ritchie K (2014) White matter hyperintensities as early and independent predictors of Alzheimer’s disease risk. JAD 42(Suppl 4):S393–S400PubMedGoogle Scholar
- Nierenberg J, Pomara N, Hoptman MJ, Sidtis JJ, Ardekani BA, Lim KO (2005) Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport 16:1369–1372View ArticlePubMedGoogle Scholar
- Pantoni L, Garcia JH (1997) Pathogenesis of leukoaraiosis: a review. Stroke 28:652–659View ArticlePubMedGoogle Scholar
- Perry ROA (1993) Coronal map of Brodmann areas in the human brain. Wolfe, LondonGoogle Scholar
- Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinisto L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN (2010) Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 75:2071–2078PubMed CentralView ArticlePubMedGoogle Scholar
- Prins ND, Scheltens P (2015) White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 11:157–165View ArticlePubMedGoogle Scholar
- Raff MC, Whitmore AV, Finn JT (2002) Axonal self-destruction and neurodegeneration. Science 296:868–871View ArticlePubMedGoogle Scholar
- Scheltens P, Barkhof F, Valk J, Algra PR, van der Hoop RG, Nauta J, Wolters EC (1992) White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer’s disease. Evidence for heterogeneity. Brain 115:735–748View ArticlePubMedGoogle Scholar
- Schmidt R, Lechner H, Fazekas F, Niederkorn K, Reinhart B, Grieshofer P, Horner S, Offenbacher H, Koch M, Eber B et al (1994) Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). Neuroepidemiology 13:308–313View ArticlePubMedGoogle Scholar
- Schmidt R, Grazer A, Enzinger C, Ropele S, Homayoon N, Pluta-Fuerst A, Schwingenschuh P, Katschnig P, Cavalieri M, Schmidt H, Langkammer C, Ebner F, Fazekas F (2011) MRI-detected white matter lesions: do they really matter? J Neural Transm 118:673–681View ArticlePubMedGoogle Scholar
- Schmierer K, Wheeler-Kingshott CA, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, Scaravilli F, Barker GJ, Tofts PS, Miller DH (2008) Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med 59:268–277PubMed CentralView ArticlePubMedGoogle Scholar
- Smallwood A, Oulhaj A, Joachim C, Christie S, Sloan C, Smith AD, Esiri M (2012) Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol 38:337–343View ArticlePubMedGoogle Scholar
- Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800View ArticlePubMedGoogle Scholar
- Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J, Upadhaya AR (2013) Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 263:S137–S145View ArticlePubMedGoogle Scholar
- Thies W, Bleiler L (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245View ArticleGoogle Scholar
- Thomas AJ, O’Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH (2002) Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 59:785–792View ArticlePubMedGoogle Scholar
- G Tosto, ME Zimmerman, JL Hamilton, OT Carmichael, AM Brickman and I Alzheimer’s Disease Neuroimaging. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement. 2015. doi: 10.1016/j.jalz.2015.05.014Google Scholar
- Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322View ArticlePubMedGoogle Scholar
- Yamamoto Y, Ihara M, Tham C, Low RW, Slade JY, Moss T, Oakley AE, Polvikoski T, Kalaria RN (2009) Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke 40:2004–2011PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas DM, Reed BR, DeCarli CS (2006) Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 67:2192–2198PubMed CentralView ArticlePubMedGoogle Scholar